uniQure Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
April 28 2021 - 7:05AM
uniQure Announces Presentations at Upcoming American Society of
Gene and Cell Therapy (ASGCT) Annual Meeting
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced that five data presentations, of which two
are oral presentations, will be delivered at the American Society
of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting being
held May 11-14.
"Our presentations at ASGCT showcase our gene
therapy expertise in hemophilia and Huntington’s disease, as well
as advantages of the AAV5 vector in dosing through pre-existing
neutralizing antibodies,” stated Ricardo Dolmetsch, Ph.D.president
of research and development at uniQure. “In addition, we look
forward to presenting preclinical data demonstrating the potential
of the miQURE technology used in our CNS product candidates to be
effective in liver-based diseases as well.”
Specific details on uniQure’s presentations at
ASGCT include:
- Title: Clinical
Outcomes in Patients With and Without Pre-existing Neutralizing
Antibodies to the Vector: 6-Month Data from the Phase 3 HOPE-B Gene
Therapy Trial of Etranacogene Dezaparvovec (Abstract
#88)Oral Session Title: Immune Responses to AAV
VectorsDate and Time: Wednesday, May 12, 6:15 –
6:30 p.m. EDT
- Title: First
Proof-of-Concept of miQURETM Based Gene Targeting in the
Liver: Lipid Lowering and Atherosclerosis Suppression by
AAV-miQURETM-Mediated ANGPTL3 Targeting (Abstract #156)Oral
Session Title: Cardiovascular and Pulmonary Gene
TherapyDate and Time: Thursday, May 13, 6:30 –
6:45 p.m. EDT
- Title: Lowering
the Pathogenic Exon 1 HTT Fragment by AAV5-miHTT Gene Therapy
(Abstract #446)Poster Session Title:
Oligonucleotide TherapeuticsDate and Time:
Tuesday, May 11, 8:00 – 10:00 a.m. EDT
- Title: Presence of
Pre-Existing Anti-Adeno-Associated Virus (AAV) Serotype 5
Neutralizing Antibodies (NABs) in Serum of Huntington Disease (HD)
Patients Was Not Associated with Detectable Anti-AAV5 Nabs in
Cerebrospinal Fluid (CSF) (Abstract #736)Poster Session
Title: Immunological Aspects of Gene Therapy and
VaccinesDate and Time: Tuesday, May 11, 8:00 –
10:00 a.m. EDT
- Title: Dynamics,
Features and Cross-Reactivity of IgG Pool Induced after AAV5 Gene
Therapy for Hemophilia B (Abstract #741)Poster Session
Title: Immunological Aspects of Gene Therapy and
VaccinesSession Date and Time: Tuesday, May 11,
8:00 – 10:00 a.m. EDT
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary gene therapies to treat patients with hemophilia B,
Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3
and other diseases. www.uniQure.com
uniQure Contacts:
FOR
INVESTORS: |
|
FOR
MEDIA: |
|
|
|
Maria E. Cantor |
Chiara Russo |
Tom Malone |
Direct: 339-970-7536 |
Direct: 617-306-9137 |
Direct: 339-970-7558 |
Mobile: 617-680-9452 |
Mobile: 617-306-9137 |
Mobile:339-223-8541 |
m.cantor@uniQure.com |
c.russo@uniQure.com |
t.malone@uniQure.com |
Uniqure NV (TG:UQ1)
Historical Stock Chart
From Jun 2024 to Jul 2024
Uniqure NV (TG:UQ1)
Historical Stock Chart
From Jul 2023 to Jul 2024